- Sleep Apnea Linked to Weaker Bones, Teeth
- Black Hairdressers May Be at High Risk From Toxic Chemicals
- Celiac Disease Could Raise Heart Risks, Study Finds
- Hit Hard by Opioid Crisis, Canadian Province Decriminalizes Small Amounts of Hard Drugs
- What Is Chromium Picolinate? Do You Really Need It?
- Many Seniors Shunned In-Home Care During Pandemic, Worsening Health
- U.S. Leads in Health Care Spending, But Is Last for Health Outcomes Among Rich Nations
- AHA News: Depression, Poor Mental Health in Young Adults Linked to Higher Cardiovascular Risks
- AHA News: Student-Athlete’s Parents Grateful for National Spotlight on Cardiac Arrest
- Biden to Lift COVID Emergencies in May
H5N1 Bird Flu Vaccine Approved

A new vaccine has been approved by the U.S. Food and Drug Administration to prevent the so-called “bird flu” virus in adults at greater-than-average risk of exposure, the FDA said.
While most strains of bird flu don’t infect people, the H5N1 virus has caused “serious illness and death in people outside of the U.S., mostly among people who have been in close contact with infected and ill poultry,” the agency said in a news release announcing the approval.
The shot, called the Influenza A (H5N1) Virus Monovalent Vaccine, has been developed “in the event that the H5N1 avian influenza virus develops the capability to spread efficiently from human to human, resulting in the rapid spread of the disease across the globe,” the FDA added.
The vaccine, produced by a Canadian subsidiary of GlaxoSmithKline, is not intended for commercial distribution, the FDA said. It’s designed to be administered in two doses given three weeks apart.
In clinical testing involving some 3,400 adults, the most common side effects included injection-site pain and swelling, muscle aches, headache and fatigue.
More information
To learn more about bird flu, visit flu.gov.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.